Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Executing well on the controllables

Kina Securities
3:27pm
February 28, 2024
KSL’s FY23 Net Profit Before Tax (PGK 175m) was +18% on the pcp and +3.5% above MorgansE. KSL’s FY23 underlying NPAT (PGK105m) was in-line with the pcp (impacted by the lift in the tax rate on PNG banks to 45% from 30%), and ~+10% above MorgansE This was broadly a good result by KSL, in our view.  Management delivered ~+20% underlying PBT growth in a more difficult net interest margin environment, with costs and bad debts being well contained. We lift our KSL FY24F/FY25F EPS forecasts by ~4%-7% on higher non-interest income and reduced cost estimates. Our target price rises to A$1.24 (previously A$1.14). KSL continues to deliver solid underlying profit growth, and trading on ~5x FY24F EPS and a >10% dividend yield, we see the stock as too cheap. ADD. We lift our KSL FY24F/FY25F EPS forecasts by ~4%-7% on higher non-interest income and reduced cost estimates. Our target price rises to A$1.24 (previously A$1.14).

Shifting gears for the new route ahead

Motorcycle Holdings
3:27pm
February 28, 2024
MTO delivered 1H24 EBITDA (pre-AASB) of A$14.2m (guidance A$14-16m); and NPAT of A$6.6m (-37% on the pcp; and -47% hoh; and -6% vs MorgansF). LFL comps vs pcp: sales -7%; GP -11%; Opex -2%; EBITDA (post-AASB) -30%; and Underlying EBITDA (pre-AASB) -%. Encouragingly, MTO pointed to improving trade through Jan-Feb; continued to grow its market share of new motorcycles (~15% in 1H24); expand its product range (CFMOTO); and will benefit from a seasonally stronger 2H within Mojo. We recently moved to a Hold recommendation given limited earnings visibility and lower confidence in the near-term outlook. While we expect improved operating performance in 2H24, we prefer to wait for greater evidence of earnings certainty before considering a more positive view.

NIM rebases as the loan book rebalances

MoneyMe
3:27pm
February 28, 2024
MoneyMe’s (MME) 1H24 result was largely per expectations as key headline operating metrics were pre-released. Total revenue of A$108m (-~11% on pcp) was achieved on a gross loan book of ~A$1.2bn (flat on the sequential half). The key positive in the result, in our view, was the continued uptick of asset quality of the book, with MME focusing on originating higher credit quality loans in recent periods. Our FY24F-FY26F EBITDA is altered by ~-19%-+6% on adjustments to our book yield estimates as secured assets become a higher proportion of the gross loan book as well as some changes to our operating costs assumptions. Our DCF/PB blended valuation (equal-weighted) and price target is lowered marginally to A$0.23 (from A$0.25) on the above changes and a valuation roll-forward. We maintain our Speculative Buy recommendation.

Good start to the year but still plenty to do

Adrad Holdings
3:27pm
February 28, 2024
AHL’s 1H24 revenue and pro forma EBITDA was in line with expectations but underlying NPAT was weaker due to higher D&A. Both segments delivered solid revenue growth with Distribution (formerly Aftermarket) up 7% and Heat Transfer Solutions (HTS) rising 8%. Key positives: Balance sheet remains healthy with net cash (ex-leases) of $15.6m; Group pro forma EBITDA margin increased 20bp to 13.5%; Operating cash flow jumped to $11.1m (vs $3.8m in the pcp) due to improved inventory management. Key negative: HTS earnings and margins were impacted by warranty issues. Management has maintained FY24 guidance for revenue and pro forma EBITDA growth of between 5-8%. Our target price decreases to $1.30 (from $1.40) and we maintain our Add rating. We expect benefits from investments in facilities, staff and rationalisation of the manufacturing footprint to deliver benefits over the long term. Trading on 8.7x FY25F PE and 4.0% yield with a strong balance sheet, we think the stock remains an attractive long-term investment opportunity.

Lower earnings base, with lower risk

Earlypay
3:27pm
February 28, 2024
EPY reported Underlying NPAT of A$2.2m and pro-forma NPAT of A$2.9m. FY24 guidance is >A$4.8m pro-forma (implied 2H24 >A$1.9m). Recent mgmt focus has been on improving risk controls and the funding structure. The recent warehouse refinance removes operational complexity and improves the cost of funds (~1%) and capital efficiency (~A$10m of capital released). Funds-in-use has lowered through 1H24, with mgmt removing areas of client risk and taking a cautious volume approach (SME credit environment weakening). We expect this leads to lower 2H24 earnings but also a lower-risk earnings base. Dividends are expected to resume in 2H24. A buy-back and/or acquisitions will also be considered. Medium term, corporate appeal exists (COGs at ~19.5% of shares). Whilst earnings have re-based and the return to growth has pushed out, EPY’s quality of earnings and balance sheet position has strengthened. The group now needs to prove that sustainable volume and earnings growth can be delivered. We have an Add recommendation but note EPY should be considered higher risk.

National launch imminent for key product

Microba Life Sciences
3:27pm
February 28, 2024
MAP released its 1H results which are tracking in-line with our expectations. The imminent national launch of the MetaPanel test through Sonic Healthcare remains a key focus. We anticipate this increased awareness to spark greater interest in microbiome-related services and products underlining the growing acknowledgment of its impact on overall health across diverse medical fields. We continue to see significant upside here as the testing and services deliver scale, and the therapeutics continues to de-risk. Speculative Buy maintained.

Detecting first Argus sales

Micro-X
3:27pm
February 28, 2024
Apart from the R&D incentive not being recognised as a receivable and the timing of project income, the 1H24 result was broadly in line with expectations. Argus sales remain the key focus and near-term catalyst. We have adjusted R&D forecasts resulting in a lower target price of A$0.25. Speculative Buy maintained.

FDA submission in sight; remains well-funded

EBR Systems
3:27pm
February 28, 2024
CY22 results were broadly in line, with opex up modestly and higher interest expense. The final Premarket Approval (PMA) module remains on track, with management confident in achieving FDA filing in 3QCY24 and approval in 1QCY25. We have made no changes to our estimates or A$1. target price. Speculative Buy recommendation maintained.

A compositional weaker result

NIB Holdings
3:27pm
February 27, 2024
NHF’s 1H24 underlying operating profit (A$144m) was +13% above consensus, but was a low quality beat driven by a Covid-19 provision release in the Australia Residents Health insurance business (ARHI). Excluding this release, the result was a bit softer than expected, particularly in the adjacent businesses (IIHI, NZ, Travel) which all came in below consensus. We lower NHF FY24F/FY25F NPAT forecasts by ~-3% on slightly softer earnings estimates in all key divisions. Our target price is set at A$8.00 (previously A$8.47). With upside to our valuation reduced, we move NHF back to our a Hold call.

Turning the ship

Cooper Energy
3:27pm
February 27, 2024
The real highlight in the 1H24 result was the progress reported at Orbost. With COE flagging continued results from debottlenecking would mitigate the need for a third absorber (which would save ~A$40m capex and deliver higher production). COE reported an impressive 1H24 result, finishing with an underlying NPAT of A$5.4m (vs Visible Alpha consensus/MorgansF -A$1.0/$4.7m). We maintain an Add rating on COE with an upgraded A$0.28ps Target Price.

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more